What is Elixir Medical?
Elixir Medical is at the forefront of vascular medicine innovation, developing groundbreaking technologies designed to address coronary and peripheral artery diseases. The company's mission is to revolutionize vascular interventions, thereby enhancing patient health outcomes and overall quality of life. Their product portfolio includes investigational devices and CE mark-approved systems, such as the DynamX Coronary Bioadaptor System and the DESyne X2 Novolimus Coronary Stent System. Elixir Medical directs its solutions towards healthcare providers and individuals impacted by cardiovascular diseases, a leading global cause of mortality.
How much funding has Elixir Medical raised?
Elixir Medical has raised a total of $5.3M across 1 funding round:
Series A
$5.3M
Series A (2005): $5.3M with participation from Invus
Key Investors in Elixir Medical
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services, founded in 1985 and headquartered in New York City.
What's next for Elixir Medical?
The substantial enterprise-level funding Elixir Medical has garnered indicates a strong trajectory for scaling its operations and advancing its product pipeline. This strategic investment is likely to fuel further research and development, expand clinical trials, and accelerate market penetration for its innovative vascular technologies. The company is well-positioned to solidify its market presence and address the significant unmet needs in cardiovascular disease treatment.
See full Elixir Medical company page
